Pressure Bio Stock Price, News & Analysis

Pressure BioSciences, Inc. (OTCQB:PBIO) has initiated negotiations for exclusive statewide licenses for its patented UltraShear Technology™ (UST™), aimed at transforming THC processing. Announced on April 21, 2023, the company seeks to sell five licenses to produce highly effective, water-soluble nanoemulsions of THC, which could enhance absorption rates significantly.

The licenses, valid for three years, assure exclusive production rights within designated states. Each license includes an upfront fee and the purchase of a custom-designed UltraShear instrument. PBIO projects to generate over $5 million in non-dilutive revenue from these sales, facilitating the production of UltraShear equipment for licensees. Strong interest in these licenses indicates potential market expansion, with additional Nano products in development for various major markets.

Pressure BioSciences (OTCQB:PBIO) has announced a strategic initiative to offer exclusive licenses for its patented UltraShear Technology (UST) for processing THC concentrates. This technology enables the creation of stable, bioavailable nanoemulsions, addressing the slow onset of THC edibles and the health concerns associated with smoking. The company is granting up to five 3-year exclusive licenses, with an upfront fee and cost for custom BaroShear processing equipment. Consumer testing shows that UST-processed THC can deliver effects significantly faster than traditional methods, with first effects appearing in as little as 1-10 minutes. This opportunity positions PBIO to lead innovation in the cannabis industry, bolstered by positive early data supporting the efficacy of its products.

Pressure BioSciences (PBIO) reported a strong performance in Q4 2022, with total revenue of $607,000, reflecting a 93% increase year-over-year. Instrument sales surged by 98% to $230,000, while consumable sales grew by 11%. The company has pivoted towards its UltraShear Technology (UST) platform, anticipating record revenue in Q1 2023, driven by progress in manufacturing capabilities and expanding contract negotiations in sectors like nutraceuticals and agrochemicals. However, the operating loss for FY 2022 increased by 17% to $4.9 million, with net losses per share improving only slightly from $(3.42) in 2021 to $(1.68) in 2022. The company remains confident in its revenue growth trajectory and aims for a NASDAQ or NYSE uplisting in 2023.

Pressure BioSciences, Inc. (OTCQB: PBIO) will host a teleconference on April 18, 2023, at 4:30 PM ET, to discuss its Fiscal Year 2022 financial results and provide a business update. The live presentation will be followed by a Q&A session. Key developments to be discussed include:

• Resolution of manufacturing capacity limitations, enabling larger UST processing contracts.
• Positive early data from a THC marketing study supporting rapid delivery of nano-THC products.
• Upcoming publications from leading academics demonstrating the advantages of UST nanoemulsified CBD.
• Three UST CBD contracts with a total value of $1.5 million planned for April.
• Progress in UST contract negotiations in cosmeceuticals and nutraceuticals.
• Anticipation of record Q1 2023 revenues with plans for capacity expansion and potential uplisting.

Pressure BioSciences, Inc. (PBIO) has renewed its collaboration with NutraLife Biosciences (NLBS), focusing on developing next-generation nutraceuticals using PBIO's patented UltraShear Nanoemulsification platform. This partnership aims to combine PBIO's advanced technology with NLBS's distribution network to enhance product offerings and market reach. The nutraceuticals market is projected to reach $991 billion by 2030, and this collaboration is expected to generate millions in incremental revenues for both companies starting in 2023. PBIO's technology promises improvements in bioavailability and product effectiveness, with peer-reviewed study results anticipated in the near future.